Uchibori K - Search Results

1

Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines.

Uchibori K, Kasamatsu A, Sunaga M, Yokota S, Sakurada T, Kobayashi E, Yoshikawa M, Uzawa K, Ueda S, Tanzawa H, Sato N. Uchibori K, et al. Int J Oncol. 2012 Apr;40(4):1005-10. doi: 10.3892/ijo.2011.1300. Epub 2011 Dec 15. Int J Oncol. 2012. PMID: 22179686 Free PMC article.

2

Non-uniformity smoothing of direct-driven fuel target implosion by phase control in heavy ion inertial fusion.

Sato R, Kawata S, Karino T, Uchibori K, Ogoyski AI. Sato R, et al. Among authors: uchibori k. Sci Rep. 2019 Apr 30;9(1):6659. doi: 10.1038/s41598-019-43221-7. Sci Rep. 2019. PMID: 31040392 Free PMC article.

3

Elective surgery for liver injury and misinserted tube into the inferior vena cava associated with chest tube replacement: A case report.

Homma H, Uchibori K, Kobori F, Kawai K, Azuma K, Suzuki S, Uchida K, Oda J. Homma H, et al. Among authors: uchibori k. Acute Med Surg. 2024 Mar 18;11(1):e943. doi: 10.1002/ams2.943. eCollection 2024 Jan-Dec. Acute Med Surg. 2024. PMID: 38500639 Free PMC article.

4

Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers.

Akita T, Ariyasu R, Kakuto S, Miyadera K, Kiritani A, Tsugitomi R, Amino Y, Uchibori K, Kitazono S, Yanagitani N, Tasaka S, Nishio M. Akita T, et al. Among authors: uchibori k. Thorac Cancer. 2024 Apr;15(10):788-796. doi: 10.1111/1759-7714.15268. Epub 2024 Feb 24. Thorac Cancer. 2024. PMID: 38400801 Free PMC article.

5

A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer.

Suzuki M, Uchibori K, Oh-Hara T, Nomura Y, Suzuki R, Takemoto A, Araki M, Matsumoto S, Sagae Y, Kukimoto-Niino M, Kawase Y, Shirouzu M, Okuno Y, Nishio M, Fujita N, Katayama R. Suzuki M, et al. Among authors: uchibori k. NPJ Precis Oncol. 2024 Feb 23;8(1):46. doi: 10.1038/s41698-024-00542-9. NPJ Precis Oncol. 2024. PMID: 38396251 Free PMC article.

6

Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.

Kiritani A, Amino Y, Uchibori K, Akita T, Harutani Y, Ogusu S, Tsugitomi R, Manabe R, Ariyasu R, Kitazono S, Yanagitani N, Nishio M. Kiritani A, et al. Among authors: uchibori k. Thorac Cancer. 2024 Feb;15(5):402-409. doi: 10.1111/1759-7714.15210. Epub 2024 Jan 16. Thorac Cancer. 2024. PMID: 38226415 Free PMC article.

7

MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF.

Kondo N, Utsumi T, Shimizu Y, Takemoto A, Oh-Hara T, Uchibori K, Subat-Motoshi S, Ninomiya H, Takeuchi K, Nishio M, Miyazaki Y, Katayama R. Kondo N, et al. Among authors: uchibori k. JCI Insight. 2023 Dec 22;8(24):e173688. doi: 10.1172/jci.insight.173688. JCI Insight. 2023. PMID: 37917191 Free PMC article.

8

Clinical characteristics of patients with KRAS mutation detected by liquid biopsy.

Amino Y, Low SK, Ninomiya H, Kiritani A, Miyadera K, Kakuto S, Akita T, Tsugitomi R, Ariyasu R, Uchibori K, Kitazono S, Yanagitani N, Nishio M. Amino Y, et al. Among authors: uchibori k. Thorac Cancer. 2023 Nov;14(33):3317-3322. doi: 10.1111/1759-7714.15123. Epub 2023 Sep 26. Thorac Cancer. 2023. PMID: 37751775 Free PMC article.

9

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors.

Ariyasu R, Kakuto S, Miyadera K, Akita T, Kiritani A, Tsugitomi R, Amino Y, Uchibori K, Kitazono S, Yanagitani N, Nishio M. Ariyasu R, et al. Among authors: uchibori k. JTO Clin Res Rep. 2023 May 4;4(6):100524. doi: 10.1016/j.jtocrr.2023.100524. eCollection 2023 Jun. JTO Clin Res Rep. 2023. PMID: 37426307 Free PMC article.

10

Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients.

Tozuka T, Yanagitani N, Yoshida H, Manabe R, Ogusu S, Tsugitomi R, Sakamoto H, Amino Y, Ariyasu R, Uchibori K, Kitazono S, Seike M, Gemma A, Nishio M. Tozuka T, et al. Among authors: uchibori k. Invest New Drugs. 2023 Jun;41(3):411-420. doi: 10.1007/s10637-023-01358-3. Epub 2023 Apr 14. Invest New Drugs. 2023. PMID: 37058183

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

54 results

Search Page